Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats

Cardiovascular Research

Volumn 110, Issue 3, 2016, Pages 371-380

  Linz, Dominik ^a,b   Hohl, Mathias ^b   Dhein, Stefan ^c   Ruf, Sven ^d   Reil, Jan Christian ^b   Kabiri, Mostafa ^d   Wohlfart, Paulus ^d   Verheule, Sander ^a   Böhm, Michael ^b   Sadowski, Thorsten ^d   Schotten, Ulrich ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^d Sanofi Deutschland GmbH   (Germany)

Author keywords

Atrial emptying function; Atrial fibrillation; Cathepsin A; Diabetes; Remodelling

Indexed keywords

BRADYKININ; CARBOXYPEPTIDASE C; CONNEXIN 43; PEPTIDE HYDROLASE INHIBITOR; PLACEBO; SAR; UNCLASSIFIED DRUG; ANGIOTENSIN II; CONNEXIN 43 PROTEIN, RAT; CTSA PROTEIN, HUMAN; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRIAL FIBRILLATION; BIOCHEMICAL ANALYSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DISEASE DURATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; HEART; HEART ATRIUM; HEART ATRIUM FUNCTION; HEART ATRIUM PACING; HEART ELECTROPHYSIOLOGY; HEART LEFT ATRIUM; HEART LEFT ATRIUM FIBROSIS; HEART MUSCLE FIBROSIS; HEART SCINTISCANNING; HISTOPATHOLOGY; MALE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RAT; SUPRAVENTRICULAR TACHYCARDIA; ZUCKER DIABETIC FATTY RAT; ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENETICS; HEART ATRIUM REMODELING; HEART RATE; METABOLISM; PATHOPHYSIOLOGY; TIME FACTOR; TRANSGENIC MOUSE; ZUCKER RAT;

ACTION POTENTIALS; ANGIOTENSIN II; ANIMALS; ATRIAL FIBRILLATION; ATRIAL FUNCTION, LEFT; ATRIAL REMODELING; BRADYKININ; CATHEPSIN A; CONNEXIN 43; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FIBROSIS; HEART RATE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; PROTEASE INHIBITORS; RATS, ZUCKER; TIME FACTORS;

EID: 84973349017     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw071     Document Type: Article

References (36)

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
2. Brand FN, Abbott RD, Kannel WB,Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985;254: 3449-3453.
3. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005;105:315-318.
4. Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004;6:367-374.
5. Kato T, Yamashita T, Sekiguchi A, Sagara K, Takamura M, Takata S, Kaneko S, Aizawa T, Fu LT. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol 2006;17:890-894.
6. Müller AL, Dhalla NS. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 2012;17:395-409.
7. Hua Y, Nair S. Proteases in cardiometabolic diseases: pathophysiology, molecular mechanisms and clinical applications. Biochim Biophys Acta 2015;1852:195-208.
8. D'Amico A, Ragusa R, Caruso R, Prescimone T, Nonini S, Cabiati M, Del Ry S, Trivella MG, Giannessi D, Caselli C. Uncovering the cathepsin system in heart failure patients submitted to Left Ventricular Assist Device (LVAD) implantation. J Transl Med 2014;12:350.
9. ChengXW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012;125:1551-1562.
10. d'Azzo A, Andria G, Bonten E, Annunziata I. Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001.
11. Ruf S, Buning C, Schreuder H, Linz W, Hübschle T, Linz D, Ruetten H, Wirth K, Sadowski T. Inhibition of CatA: an emerging strategy for the treatment of heart failure. Future Med Chem 2013;5:399-409.
12. Seyrantepe V, Hinek A, Peng J, Fedjaev M, Ernest S, Kadota Y, Canuel M, Itoh K, Morales CR, Lavoie J, Tremblay J, Pshezhetsky AV. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation 2008;117:1973-1981.
13. Hiraiwa M. Cathepsin A/protective protein: an unusual lysosomal multifunctional protein. Cell Mol Life Sci 1999;56:894-907.
14. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, Erdös EG. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension 2002;39:976-981.
15. Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. Br J Pharmacol 1999;126:613-620.
16. Hayashi I, Majima M, Fujita T, Okumura T, Kumagai Y, Tomita N, Morishita R, Higaki J, Ogiwara T. In vivo transfer of antisense oligonucleotide against urinary kininase blunts deoxycorticosterone acetate-salt hypertension in rats. Br J Pharmacol 2000;131: 820-826.
17. Ruf S, Buning C, Schreuder H, Horstick G, Linz W, Olpp T, Pernerstorfer J, Hiss K, Kroll K, Kannt A, Kohlmann M, Linz D, Hübschle T, Rütten H, Wirth K, Schmidt T, Sadowski T. Novel ß-amino acid derivatives as inhibitors of cathepsin A. J Med Chem 2012;55:7636-7649.
18. Chen J, Meng Y, Zhou J, Zhuo M, Ling F, Zhang Y, Du H,Wang X. Identifying candidate genes for Type 2 Diabetes Mellitus and obesity through gene expression profiling in multiple tissues or cells. J Diabetes Res 2013;2013:970435.
19. Järvinen V, Kupari M, Hekali P, Poutanen VP. Assessment of left atrial volumes and phasic function using cine magnetic resonance imaging in normal subjects. Am J Cardiol 1994; 73:1135-1138.
20. Nori D, Raff G, Gupta V, Gentry R, Boura J, Haines DE. Cardiac magnetic resonance imaging assessment of regional and global left atrial function before and after catheter ablation for atrial fibrillation. J Interv Card Electrophysiol 2009;26:109-117.
21. Neuberger HR, Schotten U, Verheule S, Eijsbouts S, Blaauw Y, van Hunnik A, Allessie M. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 2005;111:30-37.
22. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, Kuhn-Regnier F, De Vivie ER, Dhein S. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001;38:883-891.
23. DeChiara TM, Poueymirou WT, Auerbach W, Frendewey D, Yancopoulos GD, Valenzuela DM. Producing fully ES cell-derived mice from eight-cell stage embryo injections. Methods in Enzymology 2010;476:285-293.
24. Reil JC, Hohl M, Oberhofer M, Kazakov A, Kaestner L, Mueller P, Adam O, Maack C, Lipp P, Mewis C, Allessie M, Laufs U, Böhm M, Neuberger HR. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling. Cardiovasc Res 2010;87:485-493.
25. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95.
26. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011;91:265-325.
27. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, Finnie JW, Samuel CS, Royce SG, Twomey DJ, Thanigaimani S, Kalman JM, Sanders P. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol 2015;66:1-11.
28. Rucker-Martin C, Milliez P, Tan S, Decrouy X, Recouvreur M, Vranckx R, Delcayre C, Renaud JF, Dunia I, Segretain D, Hatem SN. Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res 2006;72:69-79.
29. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, Nattel S. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res 2009;105:1213-1222.
30. Cosson S, Kevorkian JP. Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab 2003;29:455-466.
31. Daniels A, Linz D, van Bilsen M, Rütten H, Sadowski T, Ruf S, Juretschke HP, Neumann-Haefelin C, Munts C, van der Vusse GJ, van Nieuwenhoven FA. Long-term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats. Eur J Heart Fail 2012;14:193-201.
32. Acar G, Akcay A, Sokmen A, Ozkaya M, Guler E, Sokmen G, Kaya H, Nacar AB, Tuncer C. Assessment of atrial electromechanical delay, diastolic functions, and left atrial mechanical functions in patients with type 1 diabetes mellitus. J Am Soc Echocardiogr 2009;22:732-738.
33. Wakili R, Yeh YH, Yan Qi X, Greiser M, Chartier D, Nishida K, Maguy A, Villeneuve LR, Boknik P, Voigt N, Krysiak J, Kääb S, Ravens U, LinkeWA, Stienen GJ, Shi Y, Tardif JC, Schotten U, Dobrev D, Nattel S. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol 2010;3:530-541.
34. Greiser M, Neuberger HR, Harks E, El-Armouche A, Boknik P, de Haan S, Verheyen F, Verheule S, Schmitz W, Ravens U, Nattel S, Allessie MA, Dobrev D, Schotten U. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J Mol Cell Cardiol 2009;46: 385-394.
35. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
36. Gros DT, Jarry-Guichard I, Ten Velde A. Restricted distribution of connexin 40, a gap junctional protein, in mammalian heart. Circ Res 1994;74:839-851.